<p>，/PRNewswire/ -- DJS 法律集团宣布正在代表 Hims &amp; Hers Health, Inc.（&#34;Hims &amp; Hers&#34;或&#34;公司&#34;）（纽约证券交易所代码：HIMS）的投资者调查索赔，涉及证券法的违反。</p>
<p><strong>调查详情：</strong> 本次调查的重点是公司是否发布了误导性声明和/或未能披露与投资者相关的信息。诺和诺德于 2025 年 6 月 23 日发布了一份新闻稿，宣布由于对其非法大规模配制和欺骗性营销的担忧，终止与 Hims &amp; Hers Health, Inc.的&#34;合作&#34;。根据新闻稿，&#34;FDA 解决了 Wegovy®的短缺问题，基于其结论，诺和诺德完全满足当前和预计的全国需求。为了支持患者从仿制的配制版本过渡到正品、FDA 批准的 Wegovy®，诺和诺德开始与远程医疗公司合作。在合作一个多月后，Hims &amp; Hers Health, Inc.未能遵守法律，禁止以'个性化'的虚假幌子进行大规模销售配制药物，并传播了危及患者安全的欺骗性营销。&#34;基于此，Hims &amp; Hers 的股票在 2025 年 6 月 23 日下午交易中下跌了 31.7%。</p>
<p>如果您是遭受损失的股东，请联系我们参与。</p>
<p><strong>为什么选择 DJS 法律集团？</strong> DJS 法律集团的主要关注点是通过平衡的咨询和积极的倡导来提高投资者回报。我们专注于证券集体诉讼、公司治理诉讼以及国内/国际并购评估。我们的客户是全球一些最大和最复杂的对冲基金和另类资产管理公司。我们客户的诉讼索赔是极其有价值的资产，值得尊重、关注和结果。</p>
<p>在某些司法管辖区，根据适用法律和伦理规则，本新闻稿可能被视为律师广告。</p>
<p><strong>联系方式：</strong></p>
<p>David J. Schwartz</p>
<p>DJS 法律集团</p>
<p>274 White Plains Road, Suite 1</p>
<p>Eastchester, NY 10709</p>
<p>电话：914-206-9742</p>
<p>电子邮件：[email protected]</p>
<p>来源：DJS 法律集团 LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODM5MSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDM0UFJfTkVXU19VU1BSX19fX19MQTM4Mzkx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODM5MSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDM0UFJfTkVXU19VU1BSX19fX19MQTM4Mzkx"/></p>

HIMS

<p>DJS Law Group 正在调查 Hims & Hers Health, Inc.是否存在潜在的证券欺诈违规行为，重点关注误导性陈述和未披露的信息。此次调查是在 Novo Nordisk 因对 Hims & Hers 的非法大规模配药和欺骗性营销行为的担忧而终止与其合作后进行的。这导致 Hims & Hers 的股价大幅下跌 31.7%。遭受损失的股东被鼓励联系 DJS Law Group 以参与调查</p>

<p>, /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims &amp; Hers Health, Inc. (&#34;Hims &amp; Hers&#34; or &#34;the Company&#34;) (NYSE: HIMS) for violations of the securities laws.</p>
<div class="lb-trans"><p>，/PRNewswire/ -- DJS 法律集团宣布正在代表 Hims &amp; Hers Health, Inc.（&#34;Hims &amp; Hers&#34;或&#34;公司&#34;）（纽约证券交易所代码：HIMS）的投资者调查索赔，涉及证券法的违反。</p>
</div><p><strong>INVESTIGATION DETAILS:</strong> The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk issued a press release on June 23, 2025, announced that it was terminating its &#34;collaboration with Hims &amp; Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing.&#34; According to the press release, &#34;the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims &amp; Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.&#34; Based on this, shares of Hims &amp; Hers fell by 31.7% in afternoon trading on June 23, 2025.</p>
<div class="lb-trans"><p><strong>调查详情：</strong> 本次调查的重点是公司是否发布了误导性声明和/或未能披露与投资者相关的信息。诺和诺德于 2025 年 6 月 23 日发布了一份新闻稿，宣布由于对其非法大规模配制和欺骗性营销的担忧，终止与 Hims &amp; Hers Health, Inc.的&#34;合作&#34;。根据新闻稿，&#34;FDA 解决了 Wegovy®的短缺问题，基于其结论，诺和诺德完全满足当前和预计的全国需求。为了支持患者从仿制的配制版本过渡到正品、FDA 批准的 Wegovy®，诺和诺德开始与远程医疗公司合作。在合作一个多月后，Hims &amp; Hers Health, Inc.未能遵守法律，禁止以'个性化'的虚假幌子进行大规模销售配制药物，并传播了危及患者安全的欺骗性营销。&#34;基于此，Hims &amp; Hers 的股票在 2025 年 6 月 23 日下午交易中下跌了 31.7%。</p>
</div><p>If you are a shareholder who suffered a loss, contact us to participate.</p>
<div class="lb-trans"><p>如果您是遭受损失的股东，请联系我们参与。</p>
</div><p><strong>WHY DJS LAW GROUP?</strong> DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&amp;A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.</p>
<div class="lb-trans"><p><strong>为什么选择 DJS 法律集团？</strong> DJS 法律集团的主要关注点是通过平衡的咨询和积极的倡导来提高投资者回报。我们专注于证券集体诉讼、公司治理诉讼以及国内/国际并购评估。我们的客户是全球一些最大和最复杂的对冲基金和另类资产管理公司。我们客户的诉讼索赔是极其有价值的资产，值得尊重、关注和结果。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>在某些司法管辖区，根据适用法律和伦理规则，本新闻稿可能被视为律师广告。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>David J. Schwartz</p>
<div class="lb-trans"><p>David J. Schwartz</p>
</div><p>DJS Law Group</p>
<div class="lb-trans"><p>DJS 法律集团</p>
</div><p>274 White Plains Road, Suite 1</p>
<div class="lb-trans"><p>274 White Plains Road, Suite 1</p>
</div><p>Eastchester, NY 10709</p>
<div class="lb-trans"><p>Eastchester, NY 10709</p>
</div><p>Phone: 914-206-9742</p>
<div class="lb-trans"><p>电话：914-206-9742</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>电子邮件：[email protected]</p>
</div><p>SOURCE DJS Law Group LLP</p>
<div class="lb-trans"><p>来源：DJS 法律集团 LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNzI4Jk5ld3NJdGVtSWQ9TEEzODM5MSZUcmFuc21pc3Npb25fSWQ9MjAyNTA3MjgxMDM0UFJfTkVXU19VU1BSX19fX19MQTM4Mzkx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA38391&amp;Transmission_Id=202507281034PR_NEWS_USPR_____LA38391&amp;DateId=20250728"/></p>

Hims & Hers Health, Inc.因涉嫌证券欺诈违规行为被调查 - 请联系 DJS 律师事务所以讨论您的权利 - HIMS